BrowserStack Named to Forbes 2024 Cloud 100 for The Fourth Time
BrowserStack, the world's leading software testing platform, has been named to the Forbes 2024 Cloud 100, the definitive ranking of the top 100 private cloud companies globally. This marks the fourth time BrowserStack has been honored on this prestigious list, published by Forbes in partnership with Bessemer Venture Partners and Salesforce Ventures.
"We are incredibly proud to be recognized once again as one of the world's top private cloud companies," said Ritesh Arora, co-founder and CEO of BrowserStack. "This achievement underscores our commitment to revolutionizing the software testing landscape. In the past 18 months alone, we've launched over 10 new products as part of our comprehensive Test Platform vision, empowering developers to deliver high-quality software at unprecedented speeds. We're grateful to our customers and partners for this honor—this recognition reflects their trust and support in us."
The Cloud 100 evaluation process involved ranking companies across four factors: market leadership (35%), estimated valuation (30%), operating metrics (20%), and people & culture (15%). For market leadership, the Cloud 100 enlists the help ofa judging panel of public cloud company CEOs who assist in evaluating and ranking their private company peers.
"For nine years, the Forbes Cloud 100 list has recognized the leading private cloud companies in the world, from AI to work software, infrastructure to security," said Alex Konrad, the Forbes editor of the Cloud 100. "This year's list is the strongest group of standouts yet, with revenue, valuations, and growth that will eventually make for historic IPOs."
About BrowserStack
BrowserStack is the world’s leading software testing platform powering over two million tests every day across 19 global data centers. BrowserStack helps Amazon, NVIDIA, MongoDB, Microsoft, X and over 50,000 customers deliver quality software at speed by moving testing to their Cloud. BrowserStack’s platform provides instant access to 20,000+ real mobile devices on a highly reliable cloud infrastructure that effortlessly scales as testing needs grow. With BrowserStack, Dev and QA teams can move fast while delivering an amazing experience for every customer.
Founded in 2011, BrowserStack is a privately held company backed by Accel, Bond, and Insight Partners. For more information, visit https://www.browserstack.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806141447/en/
Contacts
Media Contact
BrowserStack Press Relations Team: press@browserstack.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces Publication of Phase 3 PROMIS I and II Study Results in The Lancet Respiratory Medicine Showing Efficacy Results of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis Colonized with P. aeruginosa13.9.2024 12:00:00 EEST | Press release
Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people’s health and the quality of patients’ lives, today announced the online publication of its Phase 3 PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicinejournal. The PROMIS studies assessed the efficacy and safety of inhaled colistimethate sodium administered via the I-neb® Adaptive Aerosol Delivery System (“CMS I-neb”) as a treatment to reduce the frequency of pulmonary exacerbations in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) chronically colonized with P. aeruginosa over 12 months, compared to placebo. “The publication of these pivotal data in The Lancet Respiratory Medicine represents an important milestone in our commitment to developing innovative therapies for patients with severe respiratory diseases,” said Paola Castellani, Chief Medical Officer and R&D Head at Zambon. “For patients with NCFB, a condition with no approved treatment options, the results
Intelsat Signs Hybrid Media Deal Distributing Hearst Networks EMEA Content13.9.2024 10:00:00 EEST | Press release
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks, successfully launched a hybrid television content distribution service to deliver Hearst Networks EMEA (formerly known as A+E Networks EMEA) channels to hundreds of points across Europe thanks to its seamless satellite-terrestrial connection. “Growing global media customers like Hearst Networks EMEA want to work with a single operator that can provide seamless connections from satellite to ground-based Internet Protocol distribution networks,” said Rhys Morgan, regional vice president, EMEA, Media and Networks. “Intelsat has visibility across the full distribution network, even when it spans multiple technologies and can enable customers to reach more end users.” In order to reach a wide group of viewers, content providers typically use multiple distribution mediums such as direct-to-home (DTH), cable and IPTV. Hearst Networks EMEA needed to maximize the reach of its flagship channels, The H
NATO Support and Procurement Agency Contracts SES’s O3b mPOWER for Secure Communications Services13.9.2024 09:30:00 EEST | Press release
The NATO Support and Procurement Agency (NSPA) has awarded SES a contract to deliver secure high-performance low-latency satellite services via its medium earth orbit (MEO) constellation, enabling global missions for NATO member government organisations, agencies and military. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910404747/en/ NATO Support and Procurement Agency Contracts SES’s O3b mPOWER for Secure Communications Services (Photo: Business Wire) The MEO Global Services (MGS) award represents a three-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at USD 200M, with two one-year options. This is the first award under the Global Commercially Contracted Satellite Communications Support Partnership (GCC SATCOM SP) established by the U.S. and Luxembourg under the auspices of NSPA in 2022, opening a new era of space cooperation within NATO. The MGS will be available to all NATO countries, including
SamanTree Medical Achieves FDA Clearance for Histolog® Scanner, Ushering in a New Era of Tissue Imaging in the U.S.13.9.2024 09:00:00 EEST | Press release
SamanTree Medical, a leader in innovative surgical imaging solutions, today announced that it has received FDA 510(k) clearance of its Histolog® Scanner for imaging of the internal microstructure of tissues including, but not limited to, the identification of cells, vessels and their organization or architecture. This groundbreaking Swiss made device is designed to provide real-time, highresolution imaging of fresh tissue surfaces, offering surgeons and pathologists this information for excised tissue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240912995435/en/ The Histolog Scanner in use for rapid visualization of fresh tissue microstructures. (Photo: SamanTree Medical) The Histolog® Scanner enables real-time, ultra-fast confocal microscopy, allowing for the immediate imaging of resected tissues. This advancement aims to enable physicians to improve their efficiency. “We are thrilled to introduce the Histolog® Scanner t
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types13.9.2024 09:00:00 EEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360® for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity™ platform for response monitoring in advanced non-small cell lung cancer (NSCLC). “Our latest data featured at ESMO further highlight the value of Guardant’s technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom